Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $84.83. According to TipRanks.com, Walton is ranked #6629 out of 9418 analysts. Sanofi has an analyst consensus of ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Sanofi and Eli Lilly. We raised our fair value estimate for Novo Nordisk to DKK 640 per share from DKK 600 following a solid management outlook for 2025 that likely reflects stronger growth in GLP ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Hundreds of lawsuits allege that insulin manufacturers and pharmacy benefit managers colluded to raise prices. The ...